That paradigm officially broke on July 22, 2026. Science Corporation, led by Neuralink co-founder Max Hodak, received a CE Mark from DEKRA under the EU Medical Device Regulation, authorizing the commercial sale of the PRIMA retinal implant across 30 European countries. With the first commercial procedures slated for Germany, PRIMA is the first commercialized brain-computer interface (BCI) proven to definitively restore functional central vision.
Under the Hood: The Photovoltaic Architecture
The brilliance of the PRIMA system lies in how it delegates computational and electrical loads. Standard neural implants struggle with power delivery and thermal constraints because batteries and processors generate heat that biological tissue cannot tolerate. Science Corporation circumvents this by physically separating the system into two distinct halves:
The External Projector (The Glasses): A specialized pair of glasses houses a micro-camera that captures the user's field of view. A pocket processor processes this video feed and sends it back to the glasses, which then project the visual data as near-infrared light directly into the patient’s eye.
The Subretinal Implant (The BCI): Slipped beneath the atrophic macula during a one-hour outpatient surgery, the implant is astonishingly small—just 2mm x 2mm and 30 microns thick. It requires no internal battery and no wires. Instead, the chip houses 378 photovoltaic pixels.
When the near-infrared light from the glasses hits the implant, the photovoltaic pixels act like miniature solar panels. They convert the light photons directly into precise electrical impulses that stimulate the surviving bipolar cells in the retina. The optic nerve then carries these signals to the visual cortex. In functional terms, the glasses are an augmented reality system where the display surface is the human retina itself.
Clinical Efficacy: From Press Releases to Peer Review
The tech sector is notorious for overpromising neural capabilities, but PRIMA’s validation stems from rigorous, peer-reviewed clinical data published in the New England Journal of Medicine.
Across a multi-center European study of 38 patients who had suffered profound central vision loss:
84% of patients regained the ability to read letters, numbers, and words.
80% achieved significant visual acuity improvements of at least 0.2 logMAR (equivalent to 10 letters on the ETDRS chart).
The mean improvement across the cohort was a staggering 25.5 letters, or more than five lines of vision.
Patients who could not recognize the faces of their family members are now capable of utilizing a "zoom-in" feature on the glasses to magnify text. During the trials, one patient even managed to finish a 300-page novel using the device. Crucially, the surgical placement of the chip did not cause any decline in the patients' remaining peripheral vision.
The Sustainable Tech Perspective: Hardware Footprint in Accessibility
When analyzing the environmental impact of the tech industry, medical devices are rarely scrutinized. However, the commercialization of BCIs introduces a highly complex new category of e-waste.
On one hand, the PRIMA system represents an incredible consolidation of accessibility hardware. For the over 5 million people suffering from GA globally, severe blindness often necessitates a massive physical footprint of support tools—large optical magnifiers, dedicated text-to-speech computing hardware, and specialized environmental modifications. Replacing these bulky, plastic-heavy systems with a 2-millimeter silicon wafer and a pair of glasses dramatically reduces the lifetime hardware footprint required to navigate the world.
Conversely, BCIs rely on highly specialized, rare-earth materials and complex fabrication processes. The micro-photovoltaic cells and biocompatible coatings (often involving platinum and iridium) require energy-intensive refinement. As Science Corporation—backed by $490 million in capital—scales production for the European launch and prepares for initial US commercialization following FDA Breakthrough Device designations, the medical technology sector must establish closed-loop recycling systems for these external pocket processors and AR glasses to prevent a surge in toxic, micro-electronic medical waste.
The Future of Bio-Digital Therapeutics
The CE mark for PRIMA is not just a regulatory victory for Science Corporation; it is a turning point for the entire discipline of neuroengineering. We are crossing the threshold from pharmacological maintenance—where drugs merely delay the inevitable death of cells—to bio-digital restoration, where engineered silicon fundamentally replaces failed biological organs. As the initial rollout begins in Germany this September, the definition of irreversible blindness has officially been rewritten.